NASDAQ:BCYC

Bicycle Therapeutics Q3 2026 Earnings Results & Report

Bicycle Therapeutics logo
$3.05 -0.06 (-1.93%)
Closing price 04:00 PM Eastern
Extended Trading
$3.07 +0.02 (+0.66%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bicycle Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released October 29, 2026. The company reported EPS of -$0.15 versus the -$0.3990 consensus estimate, while revenue of $34.06 million topped the $12.22 million estimate by $21.84 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Bicycle Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.3990
Beat/Miss
Beat by +$0.2490
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Bicycle Therapeutics Revenue Results

Actual Revenue
$34.06 million
Expected Revenue
$12.22 million
Beat/Miss
Beat by +$21.84 million
YoY Revenue Growth
N/A

Bicycle Therapeutics Q3 2026 Earnings FAQ

Bicycle Therapeutics (NASDAQ:BCYC) reported earnings of -$0.15 per share for Q3 2026, beating the consensus estimate of -$0.3990. The report was announced on Thursday, October 29, 2026.

Bicycle Therapeutics reported revenue of $34.06 million for Q3 2026, against a consensus estimate of $12.22 million.

Bicycle Therapeutics Earnings Headlines

Bicycle Therapeutics (NASDAQ:BCYC) Cut to Sell at Wall Street Zen
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
See More Bicycle Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bicycle Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicycle Therapeutics and other key companies, straight to your email.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts.

The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.

Its research includes Bicycle toxin conjugates, which pair target-binding peptides with therapeutic payloads, as well as radiopharmaceutical and immune-modulating approaches. The company’s products are investigational and are being developed through clinical and preclinical research.

View Bicycle Therapeutics Profile